OptiBiotix Health plc (LON:OPTI) has announced that it is gradually transitioning from a research and development company to a commercial business and plans to open its online store by the end of April.
The AIM-listed company said it is building value within each of its three divisions, leveraging the uniqueness of its technology to commercialise food ingredients and products so that each division becomes profitable and self-sustainable.
READ: Optibiotix Health - Microbiome Specialist Entering Commercial Phase
The obesity and cholesterol management company is also building its product portfolio with partners and developing an online store to create a shop window for its technologies and products. It expects this transition to be completed by the end of April. The shop will sell GoFigure products, the wider range of SlimBiome products and LPLDL formulations.
OptiBiotix said it is all part of a gradual transition from a research and development company to a commercial business: “The overall aim is to build revenues within each division to between £5mln-£10mln per annum over the forthcoming years.”
Stephen O’Hara, CEO of OptiBiotix, said: “Industry interest is coming from national retailers and global corporates which have potential for significant upside given the scale of their market reach.”
He added: "We remain on track with our strategy of building multiple revenue streams from both consumer and pharmaceutical products across all our technology platforms."